Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Approval for Teriflunomide Tablets, 7 mg and 14 mg; Tobramycin Ophthalmic Solution USP, 0.3%. The Company has enclosed its press releases for both the products seperately.
The above information is a part of company’s filings submitted to BSE.